CHF and arrhythmias:

Indications for: BIDIL

Heart failure (HF) in black patients, as adjunct to standard treatment, to improve survival, prolong time to hospitalization for HF, and improve patient-reported functional status.

Limitations of Use:

There is little experience in patients with NYHA class IV heart failure.

Adult Dosage:

Initially 1 tab 3 times daily, may reduce to ½ tab 3 times daily if not tolerated; titrate as tolerated after 3–5 days. Max 2 tabs 3 times daily.

Children Dosage:

Not established.

BIDIL Contraindications:

Allergy to organic nitrates. Concomitant PDE5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil), or riociguat.

BIDIL Warnings/Precautions:

Correct volume/salt depletion prior to initiation. Hypotension. Hypertrophic cardiomyopathy. Discontinue if syncope occurs. Give pyridoxine if peripheral neuritis occurs. Elderly. Pregnancy. Nursing mothers.

BIDIL Classification:

Vasodilators (nitrate + direct-acting).

BIDIL Interactions:

See Contraindications. Severe hypotension with PDE5 inhibitors or riociguat.

Adverse Reactions:

Headache, dizziness, asthenia, nausea, vomiting, hypotension, sinusitis, tachycardia, paresthesia, amblyopia; SLE.

Generic Drug Availability:


How Supplied: